Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial

Adam L. Cohen1,2 · Christopher J. Anker3 · Brett Johnson2 · Lindsay M. Burt2,4 · Dennis C. Shrieve2,4 · Karen Salzman2,5 · Randy Jensen2,6 · Ken Boucher1,7 · Howard Colman2,6

Received: 8 April 2020 / Accepted: 30 May 2020 / Published online: 6 June 2020
© The Author(s) 2020

Abstract
Introduction There are no effective treatments for gliomas after progression on radiation, temozolomide, and bevacizumab. Microglia activation may be involved in radiation resistance and can be inhibited by the brain penetrating antibiotic minocycline. In this phase 1 trial, we examined the safety and effect on survival, symptom burden, and neurocognitive function of reirradiation, minocycline, and bevacizumab.

Methods The trial used a 3 + 3 design for dose escalation followed by a ten person dose expansion. Patients received reirradiation with dosing based on radiation oncologist judgment, bevacizumab 10 mg/kg IV every two weeks, and oral minocycline twice a day. Symptom burden was measured using MDASI-BT. Neurocognitive function was measured using the COGSTATE battery.

Results The maximum tolerated dose of minocycline was 400 mg twice a day with no unexpected toxicities. The PFS3 was 64.6%, and median overall survival was 6.4 months. Symptom burden and neurocognitive function did not decline in the interval between treatment completion and tumor progression.

Conclusions Minocycline 400 mg orally twice a day with bevacizumab and reirradiation is well tolerated by physician and patient reported outcomes in people with gliomas that progress on bevacizumab.

Keywords Glioma · Reirradiation · Minocycline · Bevacizumab

Introduction
Gliomas are the most frequent brain tumor, accounting for approximately 12–15% of all brain tumors [1]. Standard treatments following maximal safe resection, depending on histology, include radiation, chemotherapies such as temozolomide, CCNU, or PCV, tumor treating fields, and bevacizumab [2–5]. Recurrent gliomas remain a clinical challenge, however. In particular, once high grade gliomas have progressed following radiation, chemotherapy, and bevacizumab, no treatments are known to prolong survival. Indeed, the 6-month progression-free survival (PFS6) in such situations is generally < 10% in published studies [6, 7].

Although historically repeat fractionated radiation for gliomas was considered prohibitively toxic, modern radiation techniques allow for repeat radiation in many cases [8–14]. Several studies have directly assessed fractionated reirradiation with concomitant bevacizumab and have demonstrated its safety [15–18]. Only two groups have published
on reirradiation for high grade gliomas after progression on bevacizumab, showing a median survival of 5.4 months [19] and 4.8 months [20]. Moreover, no study has documented quality of life or cognition following repeat radiation in this population.

Studies have identified activation of nuclear factor kappa B (NFκB) as a key signaling factor promoting the mesenchymal subtype and radiation resistance in glioblastoma (GBM) [21, 22]. Activation of NFκB in glioma stem-cell cultures by tumor necrosis factor (TNF) treatment resulted in radiation resistance that can be reversed by blocking NFκB. To test the role of microglia and NFκB activation on treatment resistance in vivo, treatment with minocycline, an inhibitor of microglia activation, led to a reduction of tumor grade and down-regulation of mesenchymal markers in intracranial glioma stem cell xenograft models [22].

Minocycline is a tetracycline-derivative that is FDA approved as an antibiotic. It also has anti-inflammatory properties that are not shared by all members of the tetracycline family. Because of its known ability to cross the blood–brain barrier [23], minocycline has potential as an anti-glioma agent and as a radiation sensitizer for glioma. Minocycline inhibits matrix metalloproteinase expression by microglia, thus reducing glioma invasion and expansion [24]. Minocycline also induces glioma cell death via autophagy and apoptosis [25]. Animals treated with local administration of minocycline to tumor xenografts have improved survival [26].

The present study is a phase 1 trial of the addition of minocycline to fractionated reirradiation and bevacizumab for people with gliomas that have progressed following all standard treatments, including bevacizumab. The trial incorporated serial measurement of symptom burden and cognitive function.

Materials and methods

Study design

An open-label, single arm, Phase 1, dose-escalation and dose-expansion clinical trial was conducted with patients enrolled at a single institution. The trial included adults with radiologically proven recurrent, intracranial glioma who had been previously treated with radiation, temozolomide and bevacizumab. Progression must have been documented by Response Assessment in Neuro-Oncology (RANO) criteria [27], and patients must have been at least 6 months from prior radiation. Subjects were required to have adequate hematologic, hepatic, and renal function and a Karnofsky Performance Status (KPS) of at least 50. The protocol did not limit the size of the tumor as long as the radiation oncologist determined reirradiation was feasible. Exclusion criteria included contraindications to bevacizumab, including uncontrolled hypertension, intracranial hemorrhage, recent surgery, or non-healing wounds, and contraindications to minocycline, such as lupus or connective tissue disease. Patients were considered evaluable if they had a dose limiting toxicity (DLT) during the DLT window or if they completed at least 28 days of minocycline and two infusions of bevacizumab without a DLT. The DLT window included the radiation and 28 days afterward. During dose escalation, unevaluable patients were replaced.

Interventions

Bevacizumab was given at the standard, FDA-approved dose of 10 mg/kg IV every two weeks. Radiation was individualized based on the best judgment of the radiation oncologist. Most subjects received 3750 centigray (cGy) in 15 fractions or 4000 cGy in 20 fractions. Details of radiation planning are given in Table 2. The gross tumor volume (GTV) was defined mostly as the T1 enhancing tumor, but given the effects on MRI imaging of anti-angiogenic agents the T2/FLAIR abnormality could be included in the GTV at the judgment of the treating radiation oncologist. The median clinical target volume (CTV) margin was 0.5 cm (Range 0–2 cm). The size of the CTV and the decision of whether to include T2/FLAIR abnormality could be included in the GTV at the judgment of the treating radiation oncologist taking into consideration MRI changes over time, prior radiation, and anatomic location. The median planning treatment volume (PTV) margin was 0.3 cm (Range 0.3–2 cm). The median RT dose was 3750 cGy (Range 2000–5400 cGy) in 15 fractions (Range 5–30). Intensity modulated radiation therapy (IMRT) was used in all patients but one, who received stereotactic radiosurgery (SRS). Minocycline was taken orally twice a day starting on the day prior to radiation and continuing until progression or intolerance. Three dose levels of minocycline were tested: 100 mg twice a day, 200 mg twice a day, and 400 mg twice a day.

Safety assessments

The primary endpoint was the rate of adverse events during and up to 28 days after radiation. All patients who received a dose of minocycline were included in the safety analysis. DLTs were defined as grade 3 or intolerable grade 2 toxicities (other than anemia, lymphopenia, high cholesterol, or weight gain) related to the minocycline occurring during or within 28 days of the end of radiation.
Efficacy and PRO assessments

The secondary endpoints were progression-free survival (PFS) at three (PFS3) and 6 (PFS6) months from the beginning of study treatment, the overall response rate, and changes over time in symptom burden and cognitive function. PFS was defined from the date of start of minocycline until the day of documented disease progression or death. PFS was only assessed in patients on the maximal tolerated dose (MTD) of minocycline. Patients who declined follow-up or did not complete radiation were censored at the time of study withdrawal. Patient symptom burden and symptom interference were measured using the MDASI-BT [28]. Cognitive function was measured using COGSTATE brief battery (detection test (DET), identification test (IDN), one card learning test (OCLT), and Groton Maze Learning Test (GMLT)) [29] Symptom burden and cognitive function were measured at baseline, week 4, week 12, and week 26 before patients were seen by the neuro-oncologist or received any MRI results.

Ethics

The trial was approved by the University of Utah Institutional Review Board (IRB). It was registered on clinicaltrials.gov, NCT01580969, prior to beginning enrollment.

Results

Demographics and clinical characteristics

Twenty-three patients were screened between July, 2012 and November, 2017, of which twenty-two were eligible and enrolled on the trial. Clinical characteristics are summarized in Table 1. Six people enrolled at the 100 mg twice a day dose level, three at the 200 mg twice a day dose level and thirteen at the 400 mg twice a day dose level. All patients have completed follow up and have died. Three people enrolled at the lowest dose did not complete radiation due to patient preference despite not having any DLT, so they were replaced (Table 2).

Most patients had GBM or multiply recurrent lower grade gliomas without approved systemic treatment options. All patients treated at the 400 mg twice a day dose had either grade III or IV gliomas at initial diagnosis. Of the 22 patients, 13 had unknown IDH status, although one of these was a 1p/19q codeleted anaplastic oligodendroglioma that was presumably IDH mutated and two were GBMs with EGFRvIII mutation that were presumably wild-type. Of the rest, 6 were IDH wild-type, including 4 GBMs, 1 grade IV glioneuronal tumor, and 1 grade II astrocytoma., and three were IDH mutated, including one GBM and two anaplastic astrocytomas. The tumor that was called anaplastic oligodendroglioma histologically was 1p/19q codeleted, but the tumor that was called grade II oligodendroglioma was not 1p/19q codeleted so by current criteria would have been called an astrocytoma.

Safety

The maximum tolerated dose of minocycline in this population was 400 mg twice a day. Of the patients who started at 400 mg twice a day, nine (70%) were able to complete radiation without stopping or reducing the minocycline.

Table 1 Demographics of participants

| Characteristic                | Number | %  |
|------------------------------|--------|----|
| Gender                       |        |    |
| Male                         | 14     | 64 |
| Female                       | 7      | 32 |
| Declined                     | 1      | 5  |
| Age                          |        |    |
| Median                       | 55.5   |    |
| Range                        | 31–76  |    |
| Race                         |        |    |
| White                        | 20     | 91 |
| Declined                     | 2      | 9  |
| Ethnicity                    |        |    |
| Non-hispanic                 | 19     | 86 |
| Hispanic                     | 1      | 5  |
| Declined                     | 2      | 9  |
| KPS                          |        |    |
| 60                           | 5      | 23 |
| 70                           | 1      | 5  |
| 80                           | 11     | 50 |
| 90                           | 5      | 23 |
| Prior therapies              |        |    |
| Median                       | 3      |    |
| Range                        | 2–6    |    |
| Time from last surgery (months) |        |    |
| Median                       | 41     |    |
| Range                        | 2.3–153|    |
| Original histology           |        |    |
| Anaplastic astrocytoma       | 3      | 14 |
| Grade II astrocytoma         | 2      | 9  |
| GBM                          | 13     | 59 |
| Grade II oligodendroglioma*  | 1      | 5  |
| Anaplastic oligodendroglioma | 1      | 5  |
| Anaplastic oligoastrocytoma* | 1      | 5  |
| Grade IV glioneuronal tumor  | 1      | 5  |

*The 1p/19q was not codeleted, so by 2016 WHO criteria, these tumors would have been classified as astrocytomas

KEY: GBM glioblastoma, KPS karnofsky performance status
| Patient number | Location            | GTV                  | CTV margin (cm) | PTV margin (cm) | PTV volume (cm³) | Type     | Number of fractions planned | Total dose planned (cGy) | Number of fractions delivered | Completed radiation |
|----------------|---------------------|----------------------|-----------------|-----------------|-------------------|----------|-----------------------------|--------------------------|-----------------------------|-------------------|
| 1              | Enhancing           | 2 + FLAIR            | 0.3             | 667             | IMRT              | 15       | 3750                        | 15                       | Y                           |                   |
| 2              | FLAIR + enhancing   | 0.5                  | 0.3             | 487             | IMRT              | 20       | 4000                        | 20                       | Y                           |                   |
| 3              | Enhancing           | 2.5 + FLAIR          | 0.3             | 398             | IMRT              | 20       | 4000                        | 20                       | Y                           |                   |
| 4              | FLAIR + enhancing   | 1                    | 0.3             | 398             | IMRT              | 15       | 3750                        | 15                       | Y                           |                   |
| 5              | FLAIR + enhancing   | 1                    | 0.3             | 397             | IMRT              | 20       | 4000                        | 13                       | N                           |                   |
| 6              | Enhancing           | 1                    | 0.3             | 195             | IMRT              | 15       | 3750                        | 15                       | Y                           |                   |
| 7              | FLAIR + enhancing   | 0                    | 0.5             | 225             | IMRT              | 15       | 3750                        | 15                       | Y                           |                   |
| 8              | FLAIR + enhancing   | 0                    | 0.5             | 145             | IMRT              | 20       | 4000                        | 20                       | Y                           |                   |
| 9              | Enhancing           | 0.5                  | 0.3             | 36              | IMRT              | 15       | 3750                        | 15                       | Y                           |                   |
| 10             | Enhancing           | 0.5                  | 0.3             | 190             | IMRT              | 15       | 3750                        | 15                       | Y                           |                   |
| 11             | FLAIR + enhancing   | 1                    | 0.3             | 442             | VMAT              | 15       | 3750                        | 15                       | Y                           |                   |
| 12             | Enhancing           | 0                    | 0.3             | 148             | IMRT              | 10       | 3500                        | 10                       | Y                           |                   |
| 13             | Enhancing           | 0                    | 0.3             | 181             | VMAT              | 15       | 3750                        | 15                       | Y                           |                   |
| 14             | Enhancing           | 1                    | 0.3             | 245             | IMRT              | 22       | 4400                        | 22                       | Y                           |                   |
| 15             | FLAIR + enhancing   | 0                    | 0.3             | 394             | IMRT              | 15       | 3750                        | 5                        | N                           |                   |
| 16             | FLAIR + enhancing   | 0                    | 0.3             | 216             | IMRT              | 15       | 3750                        | 15                       | Y                           |                   |
| 17             | FLAIR + enhancing   | 1                    | 0.7             | 443             | VMAT              | 30       | 5400                        | 5                        | N                           |                   |
| 18             | FLAIR + enhancing   | 0                    | 0.3             | 81.4            | IMRT              | 15       | 3750                        | 15                       | Y                           |                   |
| 19             | FLAIR + enhancing   | 0                    | 0.3             | 100             | VMAT              | 15       | 3750                        | 15                       | Y                           |                   |
| 20             | FLAIR + enhancing   | 0                    | 0.3             | 118             | VMAT              | 15       | 3750                        | 2                        | N                           |                   |
| 21*            | Splenium            | FLAIR + enhancing    | 0.3             | 34              | VMAT              | 14       | 3500                        | 9                        | N                           |                   |
| 21             | Brachium pontis     | FLAIR + enhancing    | 0.1             | 0.3             | SRS               | 5         | 2000                        | 2                        | N                           |                   |
| 22             | Enhancing           | 0.5                  | 0.3             | 112             | VMAT              | 15       | 3750                        | 15                       | Y                           |                   |

**KEY:** IMRT: static field intensity modulated radiation therapy, VMAT: volumetric modulated arc therapy, SRS: stereotactic radiosurgery, FLAIR: fluid attenuation inversion recovery

*Patient 21 had two separate lesions radiated in two discontiguous fields on trial. All other patients had one contiguous radiation field.
Adverse events were consistent with the known side effect profiles of minocycline, bevacizumab, and radiation. Grade 3 or higher adverse events and adverse events that occurred in more than one person are summarized in Table 3. Grade 3 or higher adverse events occurred in 24% of subjects and all resolved with supportive care or holding the minocycline. No patient had symptomatic radiation necrosis or radiation necrosis requiring treatment. There were no DLTs in the dose escalation and one DLT in the dose expansion (grade 3 nausea, dehydration, and confusion possibly related to the minocycline).

**Efficacy**

PFS and OS were assessed in all patients who started treatment at the 400 mg twice a day dose. The PFS3 in this group was 64.6% (95% confidence interval (CI) 42.8–99.8%), and the PFS6 was 27.7% (95% CI 10.6–72.3%), which compares favorably with PFS3 and PFS6 seen in other trials of patients who progressed on bevacizumab. The median PFS was 3.8 months (95% CI 2.5 months–infinity), and the median OS was 6.4 months (95% CI 4.2 months–12.1 months). Radiographic responses were rare, with one person with a gemistocytic astrocytoma treated at the 100 mg twice a day dose level having a complete response and one person with a GBM treated at the 200 mg twice a day level having a partial response. For all 22 people who enrolled on the trial, the median PFS was 3.8 months (95% CI 2.5–8.1 months). The PFS3 was 65.3% (95% CI 47.5–89.8%), and the PFS6 was 35.2%, (95% CI 19.4–63.8%).

**Symptom burden and cognitive outcomes**

Compliance with the MDASI-BT was high with 100% compliance at baseline (22 out of 22 eligible patients), week 12 (nine out of nine eligible patients), and week 26 (four out

| Toxicity code | Dose Level 0: 100 mg | Dose Level 1: 200 mg | Dose Level 2: 400 mg |
|---------------|----------------------|----------------------|----------------------|
| Total patients experiencing any G3-4 AE | 0/3 | 1/3 | 3/13 |
| Diarrhea | 0 | 0 | 1 |
| Hypertension | 0 | 0 | 1 |
| Hypokalemia | 0 | 1 | 0 |
| Insomnia | 0 | 0 | 1 |
| Nausea | 0 | 0 | 1 |
| Thromboembolic event | 0 | 0 | 2 |
| Urinary incontinence | 0 | 0 | 1 |
| Total patients experiencing any G1-2 AE | 3/3 | 3/3 | 11/13 |
| Anorexia | 0 | 0 | 4 |
| Ataxia | 0 | 0 | 2 |
| Constipation | 0 | 0 | 3 |
| Cough | 0 | 0 | 4 |
| Dehydration | 0 | 0 | 2 |
| Dermatitis radiation | 1 | 0 | 2 |
| Diarrhea | 0 | 0 | 4 |
| Dizziness | 1 | 1 | 6 |
| Dysarthria | 0 | 0 | 2 |
| Edema limbs | 0 | 0 | 2 |
| Fatigue | 1 | 1 | 4 |
| Gait disturbance | 1 | 0 | 2 |
| Headache | 2 | 2 | 2 |
| Hoarseness | 0 | 0 | 2 |
| Hypertension | 1 | 2 | 1 |
| Insomnia | 0 | 0 | 2 |
| Memory impairment | 0 | 0 | 3 |
| Muscle weakness | 0 | 0 | 3 |
| Nausea | 0 | 1 | 5 |
| Nervous system disorders—Other | 0 | 1 | 2 |
| Vomiting | 0 | 1 | 3 |
of the participants' tumors or predictors of response. Furthermore, no correlative molecular studies were performed to identify either the molecular subtypes of the participants' tumors or predictors of response.

### Discussion

Our trial demonstrates the safety of reirradiation with bevacizumab and minocycline at a starting dose of 400 mg twice a day for recurrent GBM after progression on radiation, temozolomide, and bevacizumab. The trial accrued before the approval of tumor treating fields. It adds a prospective trial to the literature showing that reirradiation of high grade gliomas after bevacizumab failure can be performed with acceptable tolerability.

The only other published studies of reirradiation after progression on bevacizumab for patients with high grade glioma included retrospective analyses by Schernberg et al. (n = 13) [19] and Shi et al. (n = 30) [20] Although the median overall survival in those series (5.4 months and 4.8 months, respectively) was only slightly lower than ours (6.4 months), radiation doses were different and more radiation was performed stereotactically. In addition, the median PTV in our trial is about twice that in the Schernberg series and about eight times that in the Shi series. The retrospective nature of those series also could introduce selection bias. Thus, the survival in this prospective trial compares favorably to those series. Moreover, the one prospective trial of reirradiation in recurrent GBM for bevacizumab-naïve patients, Radiation Therapy Oncology Group (RTOG) 1205, failed to show an incremental benefit of radiation given via 35 Gy in 10 fractions when added to bevacizumab in this population [30].

Trials of systemic therapies in gliomas after progression on bevacizumab have been disappointing. For example, eribulin had a PFS1 of 20% and nintedanib has a PFS3 of 0%, compared to the PFS3 of 65% in this trial [31, 32]. Tumor treating fields, which have gone on to FDA approval and a successful phase 3 trial in upfront treatment of GBM, gave a median OS of 6 months in patients with prior bevacizumab failure in a post-hoc subgroup analysis of the EF-11 trial [3]. Although cross-trial comparison has known pitfalls, the OS curve for tumor treating fields is similar to that seen with minocycline, bevacizumab, and radiation in our trial. Thus, prospective evaluation of the benefit of minocycline is warranted.

The symptom burden and cognitive data support the tolerability of this regimen. Patients and providers might fear that additional treatments, particularly reirradiation, may prolong life at the expense of quality of life anticipating significant declines in symptoms or cognition. In this trial, the overall symptom burden and cognitive function of survivors remained stable without clinically significant changes before tumor progression. The interference of symptoms with function and quality of life did increase immediately after radiation but then returned back toward baseline over time. No other trial of reirradiation has assessed quality of life, symptom burden, or neurocognitive function systematically.

The main limitation in this trial is the inability to separate out the effects of the radiation, bevacizumab, and the minocycline. In addition to the usual difficulties with cross trial comparisons of single-arm, single-center trials, there are few other studies of radiation in bevacizumab-refractory GBM with which to compare. Survival in a small, single-arm, single institution trial such as this may not generalize. The OS in this trial does not seem markedly longer than radiation alone or tumor treating fields, suggesting further breakthroughs are needed in this population. In addition, radiation parameters in this trial were somewhat heterogeneous, as the radiation prescription was based on the individualized judgment of the radiation oncologist. However, we think this variability increases the generalizability of our results to real world practice. Lastly, tissue from immediately prior to treatment was not available, so no correlative molecular studies were performed to identify either the molecular subtypes of the participants’ tumors or predictors of response.
This trial demonstrates the safety and tolerability of minocycline, reirradiation, and bevacizumab. A recently completed Phase I trial at the University of Utah is assessing the safety and efficacy of minocycline added to radiation and temozolomide in the upfront treatment of high grade gliomas. (NCT02272270). This upfront trial includes correlative tissue and radiomic studies not possible in the recurrent setting, which will help inform the optimal population for future randomized trials. Future studies comparing radiation and bevacizumab with and without minocycline are warranted.

Conclusion

Reirradiation with bevacizumab and minocycline is safe in bevacizumab-refractory high grade gliomas. Further studies with minocycline or other radiosensitizers are indicated.

Acknowledgements

We acknowledge support of funds in conjunction with grant P30CA042014 awarded to Huntsman Cancer Institute that supported this trial.

Compliance with Ethical Standards

Conflicts of interest

All other authors declare to no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. HC declares the following: Advisory Board/Consultant: Genentech, Roche, Merck, Best Doctors, Karyopharm Therapeutics, Private Health, Orbus, Bayer, Forma Therapeutics. Research Funding (Site PI/Institutional Contract): Newlink Genetics, Plexikon, Kadmon, Orbus, Merck, DNATrix, Abbvie, Beigene, Forma Therapeutics, GCAR, Array BioPharma. ALC declares the following: Research Funding (Site PI/Institutional Contract): Abbvie, BMS, Novartis, Roche/Genentech, Merrimack, Eli Lilly, Cantex, Diffusion Pharmaceuticals, Daiichi Sankyo, H3 Biomedicine, AstraZeneca, Acrotech, Biometrix.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Dolecek T, Propp J, Stroup N, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the united states in 2005–2009. Neuro Oncol 15(suppl 5):v1–v49
2. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
3. Stupp R, Taillibert S, Kanner A et al (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318(23):2306–2316
4. Buckner JC, Shaw EG, Pugh SL et al (2016) Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 374(14):1344–1355
5. Stupp R, Wong ET, Kanner AA et al (2012) NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 48(14):2192–2202
6. Reardon DA, Desjardins A, Peters K et al (2011) Phase II study of metronomic chemotherapy with bevacizumab for recurrent...
glioabloma after progression on bevacizumab therapy. J Neuro-oncol 103(2):371–379
7. Reardon DA, Desjardins A, Peters KB et al (2011) Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 117(23):5351–5358
8. Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23(34):8863–8869
9. Fogh SE, Andrews DW, Glass J et al (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 28(18):3048–3053
10. Kim HK, Thornton AF, Greenberg HS et al (1997) Results of re-irradiation of primary intracranial neoplasms with three-dimensional conformal therapy. Am J Clin Oncol 20(4):358–363
11. Vordermark D, Kolbi O, Ruprecht K et al (2005) Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer 5:55
12. Straube C, Kessel KA, Zimmer C et al (2019) A second course of radiotherapy in patients with recurrent malignant gliomas: clinical data on re-irradiation, prognostic factors, and usefulness of digital biomarkers. Curr Treat Options Oncol 20(9):71
13. Navarra P, Minniti G, Clerici E et al. 2019. Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO). J Neurooncol, 142(1): 59–67.
14. Shen CJ, Kummerlowe MN, Redmond KJ et al (2018) Re-irradiation for malignant glioma: toward patient selection and defining treatment parameters for salvage. Adv Radiat Oncol 3(4):582–590
15. Niyazi M, Ganswindt U, Schwarz SB et al. 2010. Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys.
16. Gutin PH, Iwamoto FM, Beal K et al (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75(1):156–163
17. Flieger M, Ganswindt U, Schwarz SB et al (2014) Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. J Neurooncol 117(2):337–345
18. Hundsberger T, Brugge D, Putora PM et al (2013) Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. J Neurooncol 112(1):133–139
19. Schernberg A, Dhermain F, Ammari S et al (2018) Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients. Cancer Radiother 22(1):9–16
20. Shi W, Blomain ES, Siglin J et al (2018) Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high-grade gliomas progressed after bevacizumab treatment. J Neurooncol 137(1):171–177
21. Bhat KP, Salazar KL, Balasubramaniyan V et al (2011) The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 25(24):2594–2609
22. Vaillant BD, Bhat K, Sulman EP et al. 2012. The NFκB pathway as a key mediator of the glioblastoma mesenchymal subtype in glioblastoma stem cells and human tumors. J Clin Oncol, 30(suppl; abstr 2002).
23. Smith DL, Woodman B, Mahal A et al (2003) Minocycline and doxycycline are not beneficial in a model of Huntington’s disease. Ann Neurol 54(2):186–196
24. Markovic DS, Vinnakota K, van Rooijen N et al (2011) Minocycline reduces glioma expansion and invasion by attenuating microglial MT1-MMP expression. Brain Behav Immun 25(4):624–628
25. Liu WT, Lin CH, Hsiao M, Gean PW (2011) Minocycline inhibits the growth of glioma by inducing autophagy. Autophagy 7(2):166–175
26. Weingart JD, Sipos EP, Brem H (1995) The role of minocycline in the treatment of intracranial 9L glioma. J Neurosurg 82(4):635–640
27. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972
28. Armstrong TS, Mendoza T, Gning I et al. 2006. Validation of the M.D. anderson symptom inventory brain tumor module (MDASI-BT). J Neurooncol, 80(1): 27–35.
29. Maruff P, Thomas E, Cysique L et al (2009) Validity of the Cognitive Assessment Battery: characteristics of standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neursychol 24(2):165–178
30. Tsien C, Pugh S, Dicker AP et al (2019) Randomized phase II trial of re-irradiation and concurrent bevacizumab versus bevacizumab alone as treatment for recurrent glioblastoma (NRG Oncology/RTOG 1205): initial outcomes and rt plan quality report. Int J Radiat Oncol Biol Phys 105(1):S78
31. Norden AD, Schiﬀ D, Ahluwalia MS et al (2015) Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J Neurooncol 121(2):297–302
32. Chamberlain MC, Grimm S, Phuphanich S et al (2014) A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC). J Neurooncol 118(2):335–343

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.